866 completed. 866 Phase 2, 209 Phase 1, 19 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 866 | Completed 866 |
| Phase 1 | 209 | Completed 209 |
| Phase 3 | 19 | Completed 19 |
Follow Leukemia, Lymphoid: new trials by email Literature Review of Leukemia, Lymphoid trials Research Report on Leukemia, Lymphoid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders Hem101 - Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL | Phase 1 / Phase 2 | Completed | National Research Center for Hematology, Russia | 58 | 2024-11-26 | 2026-02-09 |
| A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic MVA-based SARS-CoV-2 Vaccine COH04S1 - Chronic Lymphocytic Leukemia, COVID-19 Infection | Phase 2 | Completed | City of Hope Medical Center | 47 | 2023-08-01 | 2026-09-09 |
| ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) ABC008 - T-cell Large Granular Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Abcuro, Inc. | 21 | 2022-09-28 | 2026-05-06 |
| A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study) IPAD, Augmented Reality - Pediatric ALL, Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 29 | 2022-08-19 | 2026-01-15 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-05-01 | 2024-04-25 |
| Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Murine autologous anti-CD19 chimeric antigen receptor T cells - Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse | Phase 2 | Completed | Beijing Boren Hospital | 2 | 2022-03-24 | 2025-05-18 |
| Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma chimeric antigen receptor T cell treatment - T-cell Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma | Phase 2 | Completed | Beijing Boren Hospital | 55 | 2021-12-01 | 2025-05-18 |
| Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy Siltuximab - Cytokine Release Syndrome, ICANS | Phase 2 | Completed | University of Alabama at Birmingham | 20 | 2021-11-15 | 2026-07-27 |
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Venetoclax, Ibrutinib, Obinutuzumab - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Completed | AbbVie | 20 | 2021-11-08 | 2026-10-21 |
| Venetoclax Based Regimen for R/R T-ALL Venetoclax combined with azacitidine regimen - Acute T-Lymphocytic Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 25 | 2021-11-01 | 2025-05-14 |
| Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings vaccine COMIRNATY® (BNT162b2) - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 76 | 2021-09-29 | 2024-06-26 |
| Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia Curcumin, Standard of Care - Acute Lymphoblastic Leukemia, Pediatric | Phase 2 | Completed | Ain Shams University | 30 | 2021-08-22 | 2024-01-08 |
| COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies A single "booster" dose of the Moderna mRNA COVID-19 vaccine - Multiple Myeloma, AL Amyloidosis | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 119 | 2021-08-17 | 2023-12-20 |
| A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL) Lyophilized S95014 - Acute Lymphoblastic Leukemia | Phase 2 | Completed | Institut de Recherches Internationales Servier | 75 | 2021-06-15 | 2023-12-29 |
| Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL BLINCYTO (Blinatumomab) - Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) | Phase 2 | Completed | University of Maryland, Baltimore | 2 | 2021-06-11 | 2025-07-03 |
| Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL Acalabrutinib - Chronic Lymphoid Leukemia | Phase 2 | Completed | German CLL Study Group | 53 | 2021-06-01 | 2025-06-08 |
| A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia) LOXO-305 - Leukemia, Lymphoid, Lymphoma, Non-Hodgkin | Phase 2 | Completed | Eli Lilly and Company | 87 | 2021-05-14 | 2026-02-06 |
| A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL) Lyophilized S95014, Liquid S95014 - Acute Lymphoblastic Leukemia | Phase 2 | Completed | Institut de Recherches Internationales Servier | 89 | 2021-05-07 | 2023-07-12 |
| Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation HSCT donor leukemia-specific cytotoxic T-cells - Acute Lymphoblastic Leukemia ALL, Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 15 | 2021-02-13 | 2025-03-07 |
| Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) Fludarabine, Bendamustine Hydrochloride, Busulfan - Leukemia, Acute Lymphoblastic, Myeloid Leukemia, Acute | Phase 2 | Completed | St. Petersburg State Pavlov Medical University | 50 | 2021-01-21 | 2024-05-07 |
Showing 20 of 866. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (509) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (452) · Leukemia (299) · Lymphoma, Non-Hodgkin (240) · Leukemia, Myeloid, Acute (228) · Lymphoma, Follicular (214) · Lymphoma (207) · Lymphoma, Mantle-Cell (190) · Lymphoma, B-Cell, Marginal Zone (184) · Lymphoma, Large B-Cell, Diffuse (174) · Burkitt Lymphoma (163) · Hodgkin Disease (161) · Myelodysplastic Syndromes (159) · Lymphoma, Large-Cell, Immunoblastic (135) · Multiple Myeloma (124)
Hemic and Lymphatic Diseases (866) · Neoplasms by Histologic Type (865) · Immune System Diseases (862) · Immunoproliferative Disorders (862) · Hematologic Diseases (860) · Lymphatic Diseases (858) · Lymphoproliferative Disorders (853) · Neoplasms (835) · Pathological Conditions, Signs and Symptoms (630) · Pathologic Processes (628) · Disease Attributes (614) · Chronic Disease (594) · Leukemia (567) · Leukemia, B-Cell (499)
Cyclophosphamide (205) · Rituximab (132) · fludarabine phosphate (125) · Peripheral Blood Stem Cell Transplantation (87) · Filgrastim (82) · Methotrexate (79) · Cytarabine (78) · Etoposide (68) · Mycophenolic Acid (67) · fludarabine (66) · Whole-Body Irradiation (61) · Tacrolimus (58) · Vincristine (58) · Busulfan (56) · Radiotherapy (56)
M.D. Anderson Cancer Center (72) · Fred Hutchinson Cancer Center (62) · National Cancer Institute (NCI) (56) · Memorial Sloan Kettering Cancer Center (26) · Mayo Clinic (21) · National Heart, Lung, and Blood Institute (NHLBI) (16) · German CLL Study Group (15) · Roswell Park Cancer Institute (13) · Alliance for Clinical Trials in Oncology (12) · Children's Oncology Group (11) · Novartis Pharmaceuticals (11) · Case Comprehensive Cancer Center (10) · H. Lee Moffitt Cancer Center and Research Institute (10) · Gruppo Italiano Malattie EMatologiche dell'Adulto (9) · Masonic Cancer Center, University of Minnesota (9)
United States (663) · Germany (71) · Italy (60) · Canada (55) · France (44) · United Kingdom (44) · Australia (28) · Spain (26) · Austria (23) · Japan (19) · Belgium (18) · China (17) · Netherlands (17) · Poland (15) · Puerto Rico (14)
Brenda Sandmaier (9) · Thomas E. Witzig, MD (6) · David Maloney (5) · Ajay Gopal (4) · Alessandra Ferrajoli, MD (4) · John Byrd (4) · Julie M Vose, MD (4) · Partow Kebriaei, MD (4)
PMID 32499241, PMID 23524640, PMID 34515338, PMID 35622074, PMID 23065508, PMID 27209293, PMID 29358183, PMID 21527516, PMID 21623761, PMID 22133778, PMID 23547837, PMID 23886836, PMID 24862638, PMID 26182309, PMID 26813675, PMID 29437592, PMID 31023700, PMID 31196847, PMID 32209572, PMID 33242441, PMID 33496754, PMID 34048072, PMID 34353848, PMID 34398557, PMID 34432863, PMID 35007144, PMID 35422096, PMID 38620092, PMID 10204198, PMID 12393429, PMID 12663715, PMID 1403051, PMID 14508361, PMID 14767498, PMID 15315963, PMID 15356646, PMID 15817673, PMID 15911237, PMID 15929131, PMID 16051743, PMID 16115130, PMID 16186597, PMID 16344315, PMID 16344317, PMID 16520464, PMID 16586495, PMID 16731764, PMID 16775235, PMID 16809737, PMID 16870552
P30CA015704 (30), U10CA031946 (16), P30CA015083 (14), P01CA018029 (13), 2009 (8), P30CA016672 (8), P30CA043703 (8), 2005 (7), 2015 (7), P01CA078902 (7), P30CA008748 (7), U10CA032102 (7), U10CA098543 (7), 2016 (6), P30CA006973 (6)